Author

T. E. Reddy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:gene regulatory network inference· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

A. Barrera· 3 shared K. C. Wood· 2 shared A. E. Stewart· 1 shared A. Gonzalez Manjon· 1 shared A. Huber· 1 shared A. M. Waters· 1 shared B. Györffy· 1 shared B. Morris· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Barrera

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers

D. P. Nussbaum, C. A. Martz, A. M. Waters, A. Barrera, J. C. Rutter, C. G. Cerda-Smith, A. E. Stewart, C. Wu, M. Cakir, C. B. Levandowski, D. E. Kantrowitz, S. J. McCall, M. Pierobon, E. Petricoin, J. J. Smith, , K. C. Wood

This study shows that Mediator kinase inhibition prevents resistance to ERK/MAPK inhibitors in KRAS-mutant cancers by blocking transcriptional plasticity.

bioRxiv · Sep 17, 2022 · PreprintCancer Biology

Cooperative regulation of coupled oncoprotein translation and stability in triple-negative breast cancer by EGFR and CDK12

H. X. Ang, N. Sutiman, X. L. Deng, L. C. Bartelt, Q. Chen, A. Barrera, J. Lin, J. Z. Sheng, I. C. McDowell, T. E. Reddy, C. V. Nicchitta, K. C. Wood

The paper identifies CDK12 inhibition as a strategy to enhance EGFR blockade efficacy in TNBC by targeting translation and stability of oncoproteins like MYC through 4E-BP1 and CCR4-NOT complex.

bioRxiv · Mar 3, 2021 · PreprintCancer Biology

Glucocorticoids regulate cancer cell dormancy

S. Prekovic, K. Schuurman, A. Gonzalez Manjon, M. Buijs, I. Mayayo Peralta, M. D. Wellenstein, S. Yavuz, A. Barrera, K. Monkhorst, A. Huber, B. Morris, C. Lieftink, J. Silva, B. Györffy, L. Hoekman, , W. Zwart

This study identifies the mechanism by which glucocorticoid receptor activation induces cancer cell dormancy through CDKN1C and FOXO1/IRS2 signaling, with implications for cancer therapy.

bioRxiv · Sep 4, 2019 · PreprintCancer Biology